Company intelligence / Profile preview

Bexorg

New Haven [4], Connecticut[4], United States[4]bexorg.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Bexorg has developed a proprietary whole-brain perfusion model and the BrainEx platform, enabling unprecedented preclinical studies on intact, metabolically active human and porcine brains. This allows for high-fidelity data collection to accelerate AI/ML-driven drug discovery in neurodegenerative diseases. The company is currently focused on early-stage research with initial emphasis on Parkinson’s and Alzheimer’s diseases.[2][3][5]

Therapeutic areas: Neurology
Modalities: Small molecules (implied by drug discovery focus)Biologics (possible, given broad CNS drug discovery platform)
Industry: Biotech

Beyond the preview

Go deeper on Bexorg.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bexorg.

Explore the full profile